TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00751244

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Affect Regulation: Guide for Education and Therapy
Description: Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy.
Study: NCT03085628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40IU
Study: NCT01425450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1020
Description: Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HF1020 placebo
Description: Single dose: HF1020 placebo capsule
Study: NCT03960580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID
Study: NCT04184414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19-CART
Description: 1-10x106 / kg CD19 CART cells
Study: NCT03962257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EngagedMD online learning platform
Description: The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
Study: NCT03751358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Erector spinae plane block
Description: Magnetic résonance imaging
Study: NCT02022215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1111 Solution, Low strength
Description: ME1111 Solution, Low strength, applied once daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1111 Solution, High strength
Description: ME1111 Solution, High strength, applied once daily for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Vehicle Solution
Description: Matching Vehicle Solution, applied once daily for 48 weeks
Study: NCT00411827

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK with conjunctival impression cytology before and after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK with conjunctival impression cytology before and after surgery
Description: LASIK with conjunctival impression cytology before and after surgery
Study: NCT01983605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARIAT Suture Delivery Device
Description: LAA exclusion procedure
Study: NCT00521599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02557958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
Study: NCT02186652

Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole
Study: NCT02249299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex Oromucosal Spray
Description: Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00751244

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy (PCT) - psychotherapy
Description: Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework.

Intervention type: OTHER
Group type: OTHER
Intervention: No-treatment waitlist group
Description: After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
Study: NCT03852940

Intervention type: OTHER
Group type: OTHER
Intervention: Parenteral nutrition

Intervention type: OTHER
Group type: OTHER
Intervention: Enteral Nutrition
Study: NCT01105195

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DuraPrep
Description: DuraPrep is used for skin preparation prior to surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: ChloraPrep is used for skin preparation prior to surgery.
Study: NCT00531817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Permitted DMARDs
Description: As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permitted DMARDs
Description: As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
Study: NCT03855098

Intervention type: OTHER
Group type: OTHER
Intervention: Biomarkers of Fruit and Vegetable Intake
Description: Cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). The following definition of portion sizes will be used; green beans (120g), lettuce (20g), spinach (90g), strawberries (96g) and blueberries (75g).~For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption.
Study: NCT03663725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified protocol
Description: Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stupp protocol
Description: RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
Study: NCT04496154

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)
Description: Triple Strength Omega-3 from Webber Naturals
Study: NCT03724084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinometostat
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinometostat
Description: Given IV
Study: NCT00866047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion
Study: NCT01792674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In situ simulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Off site simulation
Study: NCT00539448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: in combination with insulin Glulisine as bolus regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: in combination with insulin Glargine as bolus regimen
Study: NCT03590587

Intervention type: DRUG
Intervention: 0.19 mg fluocinolone acetonide (FAc) implant
Description: 0.19 mg fluocinolone acetonide (FAc) implant

Intervention type: DEVICE
Intervention: 0.19 mg fluocinolone acetonide (FAc) implant
Description: 0.19 mg fluocinolone acetonide (FAc) implant
Study: NCT01073982

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: tart cultivar Montmorency cherry juice
Description: 21 ounces of experimental or placebo juice, consumed daily for 21 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cultivar Montmorency cherry juice
Description: 21 ounces of experimental or placebo juice, consumed daily for 21 days.
Study: NCT00433849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 100μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 150μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
Study: NCT00265954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet, in-person and internet+in-person
Description: All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet, in-person and internet+in-person
Description: All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet, in-person and internet+in-person
Description: All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
Study: NCT04207385

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pharmacogenomics
Description: pharmacogenomics

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenomics
Description: pharmacogenomics

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenomics
Description: pharmacogenomics

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenomics & therapeutic drug monitoring
Description: pharmacogenomics \& therapeutic drug monitoring

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
Study: NCT01491503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: Levocetirizine dihydrochloride 5mg. PO. Single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Montelukast sodium 10mg. PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast & levocetirizine
Description: Montelukast sodium 10mg \& levocetirizine dihydrochloride 5mg PO. Single dose.
Study: NCT03059654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tracheostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tracheostomy
Study: NCT01427894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal singing with Kangaroo Care
Description: Maternal singing with Kangaroo Care
Study: NCT02700815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01945177

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narrow band imaging
Description: narrow band imaging

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: white light endoscopy
Description: white light endoscopy
Study: NCT02076880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Caloric restriction of 1000 kcal per day compared to the usual food intake.~* usual breakfast of the patient (possibly limited in quantity)~* midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No caloric restriction
Description: No change in eating habits to patients in this arm
Study: NCT03867981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based weight loss program
Description: 12-month, Internet-based weight loss/maintenance program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based weight loss program
Description: 12-month, Internet-based weight loss/maintenance program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based weight loss program
Description: 12-month, Internet-based weight loss/maintenance program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief phone coaching
Description: Some individuals will receive 3 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended phone coaching
Description: Some individuals will receive 12 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
Study: NCT01850550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss Groups
Description: The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
Study: NCT00926276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fundoplication
Description: Fundoplication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fundoplication
Description: Fundoplication
Study: NCT03520374

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasonography
Description: Ultrasonography use for the evaluation of gastric contents

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasonography
Description: Ultrasonography use for the evaluation of gastric contents
Study: NCT05104164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-myofascial release
Description: At home, the patients performed a daily session, lasting 15 minutes each, over 8 weeks. Patients accessed an ad hoc mobile application designed by the Hemophilia Physiotherapy research group (He-Foam®). This app, accessible from any smartphone, made it possible to watch the videos with all the exercises included in the intervention. The seven exercises under the specific protocol for patients with hemophilic arthropathy were: Self-release of the plantar region of the foot with a foam ball; Release of the posterior region of the leg with the foam roller; Release of the anterior leg region with a foam roller; Release of the hamstrings region with a foam roller; Release of adductor muscles with a foam ball; Release of abductor muscles with a foam roller; Release of pelvic trochanteric muscles with a foam roller
Study: NCT02154490

Intervention type: DRUG
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Intervention: Docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Intervention: FGFR Inhibitor AZD4547
Description: Given PO

Intervention type: DRUG
Intervention: FGFR Inhibitor AZD4547
Description: Given PO

Intervention type: BIOLOGICAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03371407

Intervention type: OTHER
Intervention: Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology
Description: Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions

Intervention type: OTHER
Intervention: Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology
Description: Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions

Intervention type: OTHER
Intervention: Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology
Description: Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
Study: NCT02154490

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03893240

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neutralizing Antibody to SPK-3006 capsid
Description: Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
Study: NCT02101801

Intervention type: OTHER
Group type: OTHER
Intervention: vegetables from fresh or recycled water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vegetables from fresh or recycled water

Intervention type: OTHER
Group type: OTHER
Intervention: receives vegetables from fresh water or recycled waste water farms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: receives vegetables from fresh water or recycled waste water farms